CAPR
NASDAQCapricor Therapeutics Inc.
SectorHealth CareIndustryBiotechnology: Pharmaceutical Preparations
News · 26 weeks42-67%
2025-12-142026-06-07
Mix2590d
- Insider11(44%)
- SEC Filings8(32%)
- Other3(12%)
- Earnings2(8%)
- Offering1(4%)
Latest news
25 items- INSIDERSEC Form 4 filed by CHIEF COMMERCIAL OFFICER Maurer Michael T4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
- INSIDERSEC Form 3 filed by new insider Maurer Michael T3 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Bergmann Anthony exercised 3,000 shares at a strike of $1.39, increasing direct ownership by 36% to 11,223 units (SEC Form 4)4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
- INSIDERDirector Litvack Frank exercised 3,937 shares at a strike of $1.39, increasing direct ownership by 3% to 133,776 units (SEC Form 4)4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
- SECSEC Form 10-Q filed by Capricor Therapeutics Inc.10-Q - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
- SECCapricor Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
- PRCapricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdateDeramiocel BLA under active FDA review; PDUFA target action date of August 22, 2026; labeling discussions expected to commence soonHOPE-3 Phase 3 trial met its primary endpoint (PUL v2.0; upper limb function) and all Type I error-controlled secondary endpointsGMP manufacturing facility fully operational; second-floor expansion well underway Chief Commercial Officer with direct DMD commercial experience expected to join the Company in the coming weeks Filed suit against Nippon Shinyaku Co., Ltd. and NS Pharma, Inc. seeking rescission of U.S. distribution agreement and preliminary injunction; FDA review and PDUFA date unaffectedCash balance of approximately $279 million expected to support ope
- SECCapricor Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
- INSIDEREVP, GENERAL COUNSEL Krasney Karen exercised 25,000 shares at a strike of $3.18 and sold $792,548 worth of shares (25,000 units at $31.70) as part of a pre-agreed trading plan (SEC Form 4)4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Bergmann Anthony exercised 25,000 shares at a strike of $3.18 and sold $792,540 worth of shares (25,000 units at $31.70) as part of a pre-agreed trading plan (SEC Form 4)4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
- PRCapricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12– Company to Host Conference Call on May 12, 2026, at 4:30 p.m. ET – SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that it will release its financial results for the first quarter ended March 31, 2026, after the market close on Tuesday, May 12, 2026. Management will host a conference call and webcast at 4:30 p.m. ET that same day. Title:Capricor Therapeutics First Quarter 2026 Financial Results and Recent Corporate Update Conference Call and WebcastDate:Tuesday, May 12, 2026Time:4:30 p.m. ETCall Details:Toll-Free: 1-80
- PRCapricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual MeetingSAN DIEGO, April 22, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced the presentation of data from its Phase 3 HOPE-3 clinical trial of Deramiocel in Duchenne muscular dystrophy (DMD) at the American Academy of Neurology (AAN) 2026 Annual Meeting in Chicago, Illinois. The data were presented by Dr. Aravindhan Veerapandiyan, Associate Professor and Director of the Comprehensive Neuromuscular Program at Arkansas Children's Hospital, during the Late-Breaking Science 2 session on Tuesday, April 21, 2026. AAN Presentation Highlights "No therapeutic has ever de
- SECSEC Form DEF 14A filed by Capricor Therapeutics Inc.DEF 14A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
- INSIDERSEC Form 4 filed by Sabar Karimah Es4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
- INSIDERSEC Form 4 filed by Sabar Karimah Es4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
- INSIDERSEC Form 4 filed by Krasney Karen4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
- INSIDERSEC Form 4 filed by Bergmann Anthony4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
- SECSEC Form PRE 14A filed by Capricor Therapeutics Inc.PRE 14A - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
- INSIDERSEC Form 4 filed by Krasney Karen4 - CAPRICOR THERAPEUTICS, INC. (0001133869) (Issuer)
- SECSEC Form 10-K filed by Capricor Therapeutics Inc.10-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
- SECCapricor Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
- PRCapricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate UpdateDeramiocel BLA for Duchenne muscular dystrophy under U.S. FDA review with PDUFA target action date of August 22, 2026Pivotal HOPE-3 Phase 3 trial achieved primary endpoint (PUL v2.0) and key secondary cardiac endpoint (LVEF)Late-breaking HOPE-3 data presented at MDA 2026 demonstrated additional cardiac and functional benefitsSan Diego GMP manufacturing facility operational to support potential commercial launchCapricor uplisted to the Nasdaq Global Select MarketCash balance of approximately $318 million expected to support operations through 2027Conference call and webcast today at 4:30 p.m. ET SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnol
- PRCapricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular DystrophyReduced progression of myocardial fibrosis measured by LGE on cardiac MRI (p=0.022)Significant improvement in LVEF versus placebo in patients with baseline cardiomyopathy (p=0.017)Global Statistical Test (GST) composite endpoint showed significant overall treatment benefitDuchenne Video Assessment (DVA) showed approximately 83% slowing of disease progression (p=0.018), consistent with mid-level (elbow) PUL v2.0 resultsDeramiocel BLA currently under FDA review with a PDUFA target action date of August 22, 2026 SAN DIEGO, March 12, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treat
- SECCapricor Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - CAPRICOR THERAPEUTICS, INC. (0001133869) (Filer)
- PRCapricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLADeramiocel has the potential to become the first therapy to address both skeletal and cardiac manifestations of Duchenne muscular dystrophyBLA supported by positive pivotal HOPE-3 Phase 3 results, including achievement of the primary endpoint and all Type I error-controlled secondary endpointsPDUFA target action date set for August 22, 2026; Company expects to be eligible for a Priority Review Voucher upon potential approval SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the U.S. Food and Drug Administration ("FD
CAPR FAQ
6 questionsWhat does Capricor Therapeutics Inc. do?
Capricor Therapeutics, Inc., a biotechnology company, focuses on the development of transformative cell- and exosome-based therapeutics for the treatment and prevention of a broad spectrum of diseases. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase II clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD); CAP-1002, which is in Phase II clinical trial for the treatment of cytokine storm associated with COVID-19; and completed various trials investigating the use of CAP-1002 for the treatment...Where does CAPR stock trade?
Capricor Therapeutics Inc. (CAPR) is listed on NASDAQ.What sector and industry is CAPR in?
Capricor Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about CAPR?
Capricor Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Alliance Global Partners: Buy with a $2000.00 price target on 2025-06-30. Recent price targets range from $800.00 to $3500.00.What companies are similar to CAPR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CAPR side-by-side with any of them on Quantisnow.How can I track CAPR on Quantisnow?
Quantisnow aggregates Capricor Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CAPR to receive live email and push alerts on every new disclosure.